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Intrinsically photosensitive melanopsin retinal ganglion cells (mRGCs) are crucial for non-
image forming functions of the eye, including the photoentrainment of circadian rhythms
and the regulation of the pupillary light reflex (PLR). Chromatic pupillometry, using light
stimuli at different wavelengths, makes possible the isolation of the contribution of rods,
cones, and mRGCs to the PLR. In particular, post-illumination pupil response (PIPR)
is the most reliable pupil metric of mRGC function. We have previously described,
in post-mortem investigations of AD retinas, a loss of mRGCs, and in the remaining
mRGCs, we demonstrated extensive morphological abnormalities. We noted dendrite
varicosities, patchy distribution of melanopsin, and reduced dendrite arborization. In
this study, we evaluated, with chromatic pupillometry, the PLR in a cohort of mild-
moderate AD patients compared to controls. AD and controls also underwent an
extensive ophthalmological evaluation. In our AD cohort, PIPR did not significantly differ
from controls, even though we observed a higher variability in the AD group and 5/26
showed PIPR values outside the 2 SD from the control mean values. Moreover, we found
a significant difference between AD and controls in terms of rod-mediated transient
PLR amplitude. These results suggest that in the early stage of AD there are PLR
abnormalities that may reflect a pathology affecting mRGC dendrites before involving
the mRGC cell body. Further studies, including AD cases with more severe and longer
disease duration, are needed to further explore this hypothesis.
Keywords: chromatic pupillometry, Alzheimer’s disease, melanopsin retinal ganglion cells, pupillary light reflex,
post-illumination pupil response, pupil
INTRODUCTION
Melanopsin retinal ganglion cells (mRGCs) are intrinsically photosensitive RGCs because of the
expression of the photopigment melanopsin (Berson et al., 2002; Hannibal et al., 2002; Hattar
et al., 2002). These cells contribute to non-image forming functions of the eye including circadian
photoentrainment [projecting via the retino-hypothalamic tract (RHT) to the suprachiasmatic
nucleus (SCN) of the hypothalamus] and regulation of the pupillary light reflex (PLR) [via
projections to the olivary pretectal nucleus (OPN)] (Sadun et al., 1984; Hannibal et al., 2004, 2014;
Baver et al., 2008; Chen et al., 2011; Li and Schmidt, 2018).
Frontiers in Neuroscience | www.frontiersin.org 1 August 2020 | Volume 14 | Article 780
fnins-14-00780 August 7, 2020 Time: 19:2 # 2
Romagnoli et al. Pupillometry in AD
Neurodegenerative disorders, including Alzheimer’s
disease (AD), are characterized by prominent circadian and
sleep dysfunction even in the early phase of the disease
(Uddin et al., 2020). Melanopsin retinal ganglion cell loss
demonstrated in post-mortem AD retinas may contribute to
the circadian and sleep problems documented in these patients
(La Morgia et al., 2016, 2017).
Amyloid plaques have been detected in AD retinas (Koronyo
et al., 2017) and amyloid pathology can also affect mRGCs,
suggesting a specific mechanism of neurodegeneration
independent from the aging process (La Morgia et al., 2016).
Moreover, extensive morphological abnormalities with dendrite
varicosities, patchy distribution of melanopsin, and reduced
dendrite arborization were noted in remaining mRGCs of AD
retinas (La Morgia et al., 2016).
The function of mRGCs is, however, difficult to explore in vivo,
since these cells represent a small subgroup (about 1%) of the
regular RGCs, and also mRGCs receive some input from rods and
cones (Hannibal et al., 2017). Chromatic pupillometry protocols
have been developed to isolate the contribution of mRGCs to the
PLR and to assess in vivo the function of mRGCs (Kardon et al.,
2011; Park et al., 2011; La Morgia et al., 2018). These protocols
are based on light stimuli at different wavelengths and with
light adaptation conditions aimed at isolating the contribution
of single photoreceptors, taking into account that mRGCs are
maximally sensitive to blue light at 480 nm (Berson et al., 2002).
It has been shown that the post-illumination pupil response
(PIPR) is the most reliable pupil metric of mRGC function
(Adhikari et al., 2015b).
Previous studies investigated the presence of pupil
abnormalities in AD patients but they used different visual
stimuli, heterogeneous protocols, and results were not consistent
(Chougule et al., 2019). Pre-symptomatic cases (Oh et al., 2019;
Van Stavern et al., 2019) and, recently, early AD cases (Kawasaki
et al., 2020) were evaluated with chromatic pupillometry to
isolate the mRGC contribution.
The present study was designed to evaluate the PLR, and
in particular the mRGC-mediated contribution, in AD. We
here report chromatic pupillometry findings using a previously
published protocol (Park et al., 2017) in a cohort of 26 mild-
moderate AD patients and 26 controls for which a detailed
neuro-ophthalmological evaluation has been performed.
METHODS
Study Participants
This is a cross-sectional study and follows the STROBE
guidelines (von Elm et al., 2007). We included AD patients and
healthy controls, evaluated between June 2017 and February
2020 at the IRCCS Institute of Neurological Sciences of
Bologna. All subjects gave written informed consent for the
prospective collection of clinical data, data analyses, and
publication. The study was conducted in agreement with the
Declaration of Helsinki and approved by the local ethical
committee (EC Interaziendale Bologna-Imola #16032) and
within the framework of the research project supported by
the Italian Ministry of Health, GR-2013-02358026 to CLM.
We included patients with a diagnosis of AD according to
Dubois criteria (Dubois et al., 2014) and National Institute
of Neurological and Communication Disorders–Alzheimer’s
Disease and Related Disorders Association criteria (NINCDS-
ADRDA) (McKhann et al., 1984) at mild–moderate stage [Mini-
Mental State Examination (MMSE) score between 11 and 26]
(Folstein et al., 1975).
The absence of cognitive dysfunction was ascertained in
the control group.
Exclusion criteria for both control and AD groups were:
spherical or cylindrical refractive errors more than 3 or 2 diopters,
respectively; presence of posterior pole pathology including age-
related macular degeneration and known optic neuropathies
(including open-angle glaucoma); ocular pressure more than
20 mmHg; severe lens opacity and/or retinal detachment and/or
vascular retinal pathology (including diabetic retinopathy);
history of ophthalmologic surgery, except for uncomplicated
cataract surgery, performed at least 6 months previously; shift-
workers in the last year; travels through more than one time zone
during the last 3 months.
All study participants completed self-administered
questionnaires including Epworth Sleepiness Scale (ESS),
Pittsburgh Sleep Quality Index (PSQI), Berlin questionnaire,
and Beck Anxiety (BAI) and Depression Inventory (BDI)
(Beck et al., 1961, 1988) to evaluate the possible occurrence
of sleep disturbances. For the control group, exclusion criteria
included also the presence of the following abnormal scores at
sleep and mood questionnaires: excessive daytime sleepiness
as assessed by the ESS (Vignatelli et al., 2003); presence of
sleep disturbances as determined by the PSQI (Buysse et al.,
1989); abnormal scores on the BAI (Beck et al., 1988) and BDI
(Beck et al., 1961) tests.
All subjects underwent an extensive neuro-ophthalmological
evaluation including visual acuity testing, tonometry, fundus
examination, Ishihara color vision test, and OCT examination.
OCT examination was performed using SS (Swept-Source)-
OCT with the deep range imaging (DRI) Triton OCT
(Topcon, Japan) using the 3DWide 12 × 9 mm scan protocol
including segmentation analysis. We evaluated the average
and 4 individual quadrants (temporal, superior, nasal, and
inferior) peripapillary Retinal Nerve Fiber Layer (pRNFL)
thickness, and the average and 6 individual macular sectors
(superotemporal, superior, superonasal, inferonasal, inferior, and
inferotemporal) Ganglion Cell-Inner Plexiform Layer thickness
(GCL + defined as the thickness from the inner boundary of
the GCL to the outer boundary of the inner plexiform layer
[IPL]). OCT scans were acquired by the same experienced
operator (MC) and poor-quality images (quality index less than
60), segmentation or centered errors, presence of any optic
disk abnormalities potentially interfering with the goodness
of OCT examination (presence of dysmorphic or tilted optic
disk) were rejected from OCT data analysis. Moreover, AD
patients performed neuropsychological evaluation and the
MMSE corrected (MMSEc score) was obtained for all of
them. We also collected all the clinical information available,
including concomitant medications potentially impacting on
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pupil function (Chougule et al., 2019; Kelbsch et al., 2019), for
both controls and AD patients.
Chromatic Pupillometric Protocol
Apparatus, Stimuli, and Procedures
A Ganzfeld ColorDome full-field stimulator (Espion V6,
ColorDome Desktop Ganzfeld; Diagnosys LLC, Lowell, MA,
United States) was used for the chromatic pupillometry test.
Participants were dark-adapted for 10 min prior to start of the
test. With the exclusion of patients for which only one eye
was eligible for the study, we tested the dominant eye, and the
contralateral eye was patched for monocular testing (65% of the
tested eyes were right eyes). Colored light stimuli were presented
to the tested eye and the pupil responses were recorded from the
same eye using the Ganzfeld system equipped with an integrated
pupillometer. The complete pupillometric protocol for isolating
the rod-, mRGC-, and cone-contribution is described in details
elsewhere (Park et al., 2011). For this study we considered the
following conditions, as previously reported (Park et al., 2017):
1. Rod-condition: low luminance (0.001 cd/m2) blue flash
presented in the dark;
2. Melanopsin-condition: photopically-matched red and blue
stimuli (450 cd/m2) presented in the dark;
3. Cone-condition: red flash (10 cd/m2) presented against the
rod-suppressing blue adapting field (6 cd/m2).
Stimuli consisted of short wavelength (blue, dominant
wavelength of 460–485 nm; mid = 472 nm) and long wavelength
(red, dominant wavelength of 620–645 nm; mid = 632 nm)
light-flashes of 1 s duration. The integrated pupillometer system
measured the pupil diameter at a 100 Hz sampling frequency.
The interstimulus interval (ISI) was 20 s for the rod- and
cone-conditions (for both red and blue stimuli), while for
the melanopsin-condition ISI was 30 s for red stimulus and
70 s for the blue one. All recordings were completed in the
same order with the red stimulus followed by the blue. For
all three conditions, each stimulus was presented three times
consecutively and the individual responses were obtained by
their average recording. Participants were instructed to keep
their eyes open during the duration of the light stimuli as well
as following the stimuli. Participants who blinked frequently
during the recordings were given another opportunity to repeat
the measurements. Pupil traces with excessive artifacts due to
long eye blinks or eye closure were excluded from subsequent
pupillometric data analysis.
Data Analysis
Data were analyzed using custom scripts programmed in
MATLAB (MathWorks Inc., Natick, MA, United States), which
allowed for semi-automated analysis. PLR was normalized by
the median steady-state (baseline) pupil size during the 2 s
preceding each stimulus onset in order to minimize the effects
of inter-subject differences in the baseline pupil size.
The following pupillometric parameters were calculated:
I. Transient PLR amplitude (or Transient Peak Amplitude)
was defined as the difference between the normalized
baseline and the minimum normalized PLR after stimulus
onset (pupil maximum constriction);
II. For the melanopsin-condition, the PIPR was used for
evaluating the mRGC sustained response. PIPR parameter
was defined as the difference between the normalized
baseline and the median normalized PLR measured over
a 5 to 7 s time interval from stimulus offset. In particular,
we evaluated PIPR from the blue and the red photopically-
matched stimuli, and also the difference between the
blue PIPR and the red one (PIPRNormalized = PIPRBlue -
PIPRRed).
Statistical Analysis
The Shapiro-Wilk and Kolmogorov–Smirnov tests were
performed to assess the normal distribution and graphic
inspection of the data. Chi-square and independent-t tests
were used to compare variables among groups. For continuous
variables (pupillometric parameters), z-scores (standard scores)
were also calculated. Levene’s test was used to assess the equality
of variances for mRGC sustained response for control and
AD groups. Comparisons between groups for all pupillometric
variables, measured under rod-, melanopsin-, and cone-mediated
conditions, were computed by means of analysis of covariance
(ANCOVA) with age as the covariate. Moreover, the p-value for
interaction age × group was computed from the log-likelihood
ratio test comparing ANCOVA models with and without the
interaction term, and stratified β coefficients (95% Confidence
Interval, 95% CI) for the variables turning out to be effect
modifiers (p-value for interaction < 0.15) were presented.
For OCT data, we followed “one-eye” approach by evaluating
the eye tested by chromatic pupillometry. Pearson correlation
coefficients were used to measure the degree of association
between pupillometric parameters and clinical data (OCT
measures, MMSEc score, and disease duration) in control and
Alzheimer’s groups. Statistical analyses were performed using
SPSS (SPSS Inc., IBM, Chicago, IL, United States) and Stata SE
(StataCorp, College Station, TX, United States) softwares.
RESULTS
This study included 26 mild-moderate AD patients from 52 to
88 years of age (69.3 ± 7 years) and 26 healthy participants
(controls) from 58 to 82 years of age (70.2 ± 11 years). The
demographic and clinical data of the two groups are shown in
Table 1. Controls and AD patients did not significantly differ in
terms of age and gender (gender, p = 0.58; age, p = 0.75).
Raw pupil traces from two controls showed excessive blink
artifacts under the rod- (blue flash) and melanopsin- (blue flash)
conditions and were removed from data analysis. Further, four
control and six AD pupil traces under the cone-condition showed
too many artifacts, were not reliable, and thus were removed
from data analysis.
The single normalized pupil traces (PLR curves) under all
conditions are shown in Figure 1. For the rod- (Figures 1A,B)
and cone- (Figures 1G,H) conditions, the PLR is characterized
by a rapid transient constriction followed by a relatively rapid
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TABLE 1 | Sociodemographic data.
Controls Alzheimer’s p-value
N 26 (50%) 26 (50%)
Gender
Male 11 (42.3%) 14 (53.8%) 0.58
Female 15 (57.7%) 12 (46.2%)
Age | Age-class 69.3 ± 7 70.2 ± 11 0.75 | 0.16
50–59 years 3 (11.5%) 6 (23.1%)
60–69 years 10 (38.5%) 4 (15.4%)
70–79 years 10 (38.5%) 9 (34.6%)
80–89 years 3 (11.5%) 7 (26.9%)
MMSEc / 20.7 ± 4 /
(17.5–24.8)
Disease duration / 3.8 ± 2.9 /
(2–4.2)
Values are given as n (%) or mean ± standard deviation (interquartile range, Q1–
Q3). MMSEc, Mini Mental State Examination corrected score. Chi-square test was
performed with categorical variables and independent-t test was performed with
continuous variables.
return to the baseline both in controls (Figures 1A,G) and in AD
(Figures 1B,H).
Under the melanopsin-condition (blue flash), in both controls
(Figure 1C) and AD (Figure 1D), the PLR is characterized
by an initial transient constriction followed by a sustained
constriction (PIPR) during the 5–7 s time interval from
light-stimulus offset. Melanopsin-mediated sustained response
is more variable in the AD group (Figure 1D) compared
to the control group (Figure 1C). In fact, the estimated
population variances of the PIPR at 5-s from stimulus offset
of the two groups were statistically different (Levene’s test:
SD control = 0.03, SD AD = 0.06; p = 0.018) and, in
particular, the variability in the AD group resulted significantly
greater. Moreover, five AD patients showed a PIPR lower
more than 2 SD from the control mean value. Under the
melanopsin-condition (red flash), in both controls (Figure 1E)
and AD (Figure 1F), the elicited PLR is characterized
by an initial transient constriction, followed by a smaller
sustained response with a reduced amplitude in the AD group
compared to controls.
The individual pupillometric parameters for controls and
AD for the three conditions are provided in Figure 2. There
was no difference between AD and control groups in terms of
baseline normalized pupil size under any of the three conditions
(Figures 2A,C,G and Supplementary Table 1). PLR transient
amplitude (Figures 2B,E,F and Supplementary Table 1) was
significantly decreased under rod- (p = 0.006) and melanopsin-
(blue flash, p = 0.02; red flash, p = 0.006) conditions in AD
compared to controls. PIPRBlue in the melanopsin-condition was
not significantly different between AD and controls (Figure 2D
and Supplementary Table 1). PLR transient amplitude was not
significantly different between AD and controls under the cone-
condition (Figure 2H and Supplementary Table 1).
Figure 3 shows the mean normalized pupil traces of
rod- (Figure 3A), melanopsin- (Figure 3B), and cone-
(Figure 3C) conditions for each subject group. We failed to
observe any difference in terms of PIPRBlue and PIPRNormalized
(Supplementary Table 1) between AD and controls.
To check the extent to which the control- and AD-regression
lines of each pupillometric parameters with age deviate from
parallel, the likelihood-ratio test was used (Supplementary
Tables 2, 3 and Supplementary Figure 1). Likelihood-ratio
test showed the existence of interaction age × group for
melanopsin-mediated PIPRBlue (Alzheimer’s group: β = -0.0042;
95% CI = -0.0073–0.0011; r = -0.5) and transient peak
amplitude (Alzheimer’s group, blue flash: β = -0.0034; 95%
CI = -0.0055–0.0014; r = -0.59; red flash: β = -0.0021; 95%
CI = -0.0039–0.0003; r = -0.44) parameters with a significant
correlation only in AD (Supplementary Tables 2, 3 and
Supplementary Figures 1B,D,F).
Furthermore, Pearson’s correlation analysis was used to
determine if there was a relationship between the calculated
pupillometric parameters and OCT measures, MMSEc score,
and disease duration (the latter two only for AD). There was
no significant correlation between pupillometric parameters
and OCT measurements, neither with MMSEc score and
disease duration for AD patients. Mean comparisons of OCT
measurements for all RNFL quadrants (temporal, superior, nasal,
and inferior) and macular GCL + sectors (superotemporal,
superior, superonasal, inferonasal, inferior, and inferotemporal)
did not show significant differences between AD and controls
(data not shown).
We also retrieved information regarding oral medications
that could potentially interfere with pupillary responses,
i.e., cholinesterase inhibitors for AD and beta-blockers
for controls. Only a few controls (n = 4, 15.5%) were
on beta-blockers (atenolol/metaprolol/bisoprolol), while
16 AD (61.5%) were on cholinesterase inhibitors drugs
(donepezil/rivastigmine/galantamine). In controls, there were
no differences in terms of pupillometric parameters between
subjects taking beta-blockers and those not taking them (data
not shown). No significant differences among AD subgroups
(cholinergic-treated and cholinergic-untreated) for any PLR
parameters were found (data not shown).
DISCUSSION
In this paper, we evaluated for the first time, using chromatic
pupillometry, aimed at isolating the mRGC contribution (Park
et al., 2017), the PLR in a cohort of 26 definite mild-moderate
AD patients compared to a group of age- and gender-matched
controls. In particular, to specifically target mRGC function, we
evaluated the PIPR amplitude using intense (450 cd/m2) blue
(472 nm) light stimuli. The PIPR, which is the most reliable
marker of mRGC-mediated PLR, was not significantly different
between AD and controls, but we found a significant difference
in terms of transient PLR amplitude between AD and controls
under dark-adaption. Concerning the PIPR, even though the
difference between AD and controls was not significantly
different, the AD group showed higher variability with five
individuals having a PIPRBlue amplitude value outside the 2
SD range from the control mean. Such variability in terms of
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FIGURE 1 | Single and mean pupillometric waveforms for the rod, melanopsin, and cone conditions in controls and AD. Pupillometric traces obtained under the rod
(A,B), melanopsin (C,D, blue and E,F, red), and cone (G,H) conditions of the chromatic pupillometric protocol. Light blue (A–D) and red (E–H) traces represent
single individuals, while black traces (A–H) represent the mean waveforms for each group (A,C,E,G for the control group; B,D,F,H for Alzheimer’s group). The vertical
dotted lines indicate the time interval (5–7 s from stimulus offset) in which the melanopsin-mediated (sustained) amplitude (PIPR, Post-Illumination Pupil Response,
450 cd/m2) was measured. The light stimulus onset and offset are represented by the gray boxes along the x-axes.
disease severity has been already reported in terms of circadian
measurements and optic nerve pathology (La Morgia et al., 2016)
and might depend on the severity as well as on disease duration
(Hatfield et al., 2004). In this study we included AD patients
in a mild-moderate stage of the disease and disease severity
and duration were on average lower than previously published
cohorts (La Morgia et al., 2016). In rodents, six different mRGC
subtypes were characterized, and PLR was mainly regulated by
the Brn3b-positive M1 and non-M1 subtypes (Chen et al., 2011;
Li and Schmidt, 2018). In humans, Hannibal and colleagues also
identified six subtypes of mRGCs (M1, M2, M3, M4, giant M1,
and giant displaced M1), unevenly distributed across the human
retina and with distinct anatomical characteristics (Hannibal
et al., 2017). We previously demonstrated in post-mortem AD
retinas that mRGCs are lost in AD and amyloid pathology
specifically affects these cells (La Morgia et al., 2016). However,
it is not known whether in AD the neurodegenerative process
affects a specific mRGC subtype, and in particular those mRGC
contributing to the PLR.
Interestingly, we found a significant difference in terms
of transient peak amplitude both under the rod-condition,
using the short duration, narrowband pulse, and low intensity
(0.001 cd/m2) blue light stimulus, and under the melanopsin-
condition, but not in the cone-condition, overall pointing to
a prominent rod-mediated response (McDougal and Gamlin,
2010; Kostic et al., 2016; Krishnan et al., 2020). Considering that
mRGCs receive synaptic input from rods and cones through
bipolar cells and a direct contact of rod bipolar cells via
ribbon synapses in the ON layer of the IPL with mRGCs has
been demonstrated in human retinas (Hannibal et al., 2017),
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FIGURE 2 | Pupillometric parameters for controls and AD. Panels show scatterplots with horizontal solid line represents the mean and error bars representing
standard deviations for each group. (A,B) Show the results for the Rod-condition; (C–F) Show the results for the Melanopsin-condition [(C–E) 450 cd/m2,
472 nm-blue; (F) 450 cd/m2, 632 nm-red]; (G,H) Show the results for the Cone-condition. (A,C,G) Show normalized pupil size at baseline. (B,E,F,H) Show
normalized transient peak amplitude. (D) Show normalized melanopsin-mediated Post-Illumination Pupil Response (PIPRBlue). Peak amplitude (transient peak
amplitude) was defined as the difference between the normalized baseline pupil size and the median normalized PLR at the point of maximum pupillary constriction
after stimulus onset. PIPR was defined as the difference between the normalized baseline pupil size and the median normalized PLR measured over a 5 to 7 s time
interval from stimulus offset. Significant different between controls and AD patients are indicated by an asterix symbol above the groups. *p < 0.05; **p < 0.01.
this difference between AD and controls could suggest that in
the early stages of the disease there is no obvious cell body
dysfunction but possibly a dendropathy. This suggestion is
based on the presence of mRGC dendrite pathology, previously
reported in AD, with extensive morphological abnormalities
in the spared mRGCs showing dendrite varicosities, patchy
distribution of melanopsin, and reduced dendrite arborization
(La Morgia et al., 2016). Dendritic degeneration has been
also documented in RGCs of AD mouse model (Williams
et al., 2013), and there are other disease models such as
OPA1-related optic atrophy in which dendrites are the primary
site of pathology (Williams et al., 2010). The different mRGC
subtypes are distinctively connected to rods and cones and
specifically modulated by various light conditions (Weng
et al., 2013). Furthermore, the presence of a contact from
amacrine cells and directly from rod bipolar cells via ribbon
synapses on M1, M2, and M4 soma membrane and dendrites
has been demonstrated in human retinas (Hannibal et al.,
2017). The significantly reduced transient peak amplitude in
conditions exploring the rod-contribution may thus suggest
an altered contact between rods and mRGCs. It is possible
to hypothesize that the rod response depends more on the
distal dendrites, and consequently that the subsequent reduced
dendritic arborization might interfere with the rod input out
of proportion to the cones. However, we cannot exclude that
the rod-mediated mRGC dysfunction in AD can be due to
pathology specifically affecting rod-bipolar cells while possibly
sparing cone-bipolar cells.
In summary, pathology often provokes compensation. This
is particularly true with the central nervous system, which has
many gain control circuits in place (Ostergaard et al., 2007; Do,
2019). Therefore, if disease, injury, or aging causes a reduction
of units, there are many means for restoring the overall average
mass effect. However, with coarser granularity, there is increased
variability (Mendell, 2014). In this case, fewer mRGCs or even
fewer dendritic circuits give less granularity in the system and
a tendency for larger swings in the response. Thus, variability
would precede decompensation into failure.
Baseline pupil size was not significantly different between
AD and controls. It must be considered, however, that 16/26
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FIGURE 3 | Mean pupillometric waveforms obtained under the rod, melanopsin, and cone conditions in controls and AD. (A) Shows PLR measured under the
rod-condition with the short- (blue) wavelength flashes (0.001 cd/m2) presented in the dark, for comparison between control (blue mean trace) and AD (azure mean
traces) groups. (B) Shows PLR measured under the melanopsin-condition, including the two photopically-matched intense long- (red) and short- (blue) wavelength
flashes (450 cd/m2) presented in the dark, for comparison between control (red and blue mean traces) and AD (pink and azure mean traces) groups. The vertical
dotted lines indicate the time interval (5–7 s from stimulus offset) over which the melanopsin-mediated (sustained) amplitude (PIPR) was measured. (C) Shows PLR
measured with the long- (red) wavelength flashes (10 cd/m2) presented against the rod-suppressing blue adapting field (6 cd/m2) for comparison between control
(red mean trace) and AD (pink mean trace) groups.
AD patients were on acetylcholinesterase inhibitor drugs,
and this might have an impact on the baseline pupil size.
A few, small sample studies have reported the effect on the
PLR of commonly used cholinergic AD drugs (Fotiou et al.,
2000; Granholm et al., 2003). In one of these studies the
authors did not find an effect of cholinergic medications
on baseline pupil size, but demonstrated an increase in
pupil constriction latency (Granholm et al., 2003). We
also compared the PLR in AD patients taking and not
taking these drugs and failed to demonstrate significant
differences. Additional studies are needed to conclude a
real effect of cholinergic medications on PLR and to clarify
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if different acetylcholinesterase inhibitors could have a
different impact on PLR.
Previous studies investigated PLR in AD patients
documenting reduced velocity, constriction amplitude, and
increased latencies of PLR. These results were interpreted as
related to the acetylcholine deficiency and parasympathetic
dysfunction in AD (Prettyman et al., 1997; Fotiou et al., 2000,
2007, 2009; Tales et al., 2001; Granholm et al., 2003; Frost S. et al.,
2013; Frost S.M. et al., 2013; Frost et al., 2017; Bittner et al., 2014;
Chougule et al., 2019). Unfortunately, none of these studies were
based on chromatic pupillometry protocol, and these results
were not confirmed by more recent studies, which focused on
early and pre-clinical stages of AD (Chougule et al., 2019). One
chromatic pupillometry study evaluated pre-symptomatic AD
cases (Oh et al., 2019). Oh and co-authors evaluated the PLR
response using a similar pupillometric protocol in a cohort
of 10 pre-symptomatic AD cases, defined on the basis of the
cerebrospinal fluid markers, and they did not demonstrate a
significant difference between pre-symptomatic AD cases and
controls (Oh et al., 2019). However, congruent to the current
findings, higher variability of PLR was documented in the AD
group (Oh et al., 2019). Moreover, in this study the authors
used only the 2.3 log cd/m2 photopically-matched red and blue
stimuli (Oh et al., 2019). Similarly, Van Stavern and co-authors,
using a white light stimulus, did not show any difference between
preclinical AD subjects (defined by CSF markers) and normal
aging controls in any of the PLR parameters examined (Van
Stavern et al., 2019). Very recently, Kawasaki et al. (2020), using
a different chromatic pupillometry protocol under photopic
conditions, failed to demonstrate, similarly to our results, a
significant difference between early AD and controls in terms of
PIPR response.
We also demonstrated a significant correlation of the PIPR
amplitude and transient peak amplitude (melanopsin-condition,
450 cd/m2) with age only in the AD group, which is in line
with previous results pointing to an accelerated aging process
in AD (La Morgia et al., 2016). Data on PLR in relation to
age are not conclusive even though the majority of papers
failed to reveal a significant difference of PLR in relation to the
aging process. However, the controls included in these studies
were younger than 70, and this might explain the absence of
significant impairment of the pupil response (Adhikari et al.,
2015a; Rukmini et al., 2017). Our results are in line with the
observation of mRGC loss with age (Semo et al., 2003; La Morgia
et al., 2016; Esquiva et al., 2017).
We did not find a correlation between pupil metrics and OCT
parameters nor with disease severity or duration. Moreover, we
did not find any significant difference in terms of RNFL and
GCL + thickness between AD and controls. Any effect specific
to mRGC loss would have been swamped by regular RGCs in
these measures. Further, these results can be explained by the
inclusion of milder cases with shorter disease duration. A recent
SS-OCT study evaluating a large cohort of AD cases failed to
demonstrate a significant difference in terms of RNFL between
AD and controls (Sanchez et al., 2018).
Overall, the current chromatic pupillometry findings in a
cohort of mild-moderate AD patients did not demonstrate a clear
mRGC-driven pupil dysfunction but are rather consistent with a
dendropathy in the early stage of the disease, supported by our
previous post-mortem studies of AD retinas. Early pathology,
while still in the range of compensatory mechanisms, often
manifests as variability. Further studies including more severe
and with longer disease duration AD cases are needed to further
explore this hypothesis. Such studies may also clarify whether the
PLR can be used as a tool evaluating the progression of the disease
and eventually the efficacy of therapies in AD.
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